Ibalizumab shows in-vitro activity against group A and group B HIV-2 clinical isolates

Conclusion: Ibalizumab inhibits HIV-2 replication, with IC50 and MPI in the range of those reported for HIV-1. These in vitro data support the use of ibalizumab in patients with MDR HIV-2, in combination with an optimized background regimen.
Source: AIDS - Category: Infectious Diseases Tags: BASIC SCIENCE: CONCISE COMMUNICATION Source Type: research